From Pulse 2.0 · Amit Chowdhry · · 1m 20s
Sanyou Bio Secures $15M Series C Funding for AI Drug Discovery
Sanyou Bio's AI-powered drug discovery platform gains $15 million (RMB 100 million) Series C funding to expand its technology and partnerships.
In brief
Sanyou Bio's AI-powered drug discovery platform gains $15 million (RMB 100 million) Series C funding to expand its technology and partnerships. Sanyou Bio received $15 million (RMB 100 million) Series C funding from Zero2IPO Industry Investment to advance its AI drug discovery platform. Originally reported by Pulse…
Sanyou Bio Completes Series C Funding
Sanyou Biopharmaceuticals, a Shanghai-based biotechnology company, secured nearly $15 million (RMB 100 million) Series C funding from Zero2IPO Industry Investment.
Funding Expands AI Drug Discovery Platform
The round supports Sanyou Bio's integrated drug research and development platform, including antibody discovery technology and ai-driven laboratory systems.
Three Core Technology Platforms
Sanyou Bio's strategy centers on AI-Super-Trillion Antibody Library, Sanyou AI-Drug Accelerator, and Clicklinks for drug discovery.
AI-Super-Trillion Antibody Library
The AI-STAL platform contains approximately 11 trillion molecular candidates for future therapeutic products.
Sanyou AI-Drug Accelerator
SAI-DA combines computational drug discovery with wet-laboratory processes to accelerate preclinical research.
Clicklinks Collaboration Platform
Clicklinks connects pharmaceutical companies, biotech developers, and research partners for collaborative drug discovery projects.
Global Partnerships and Projects
Sanyou Bio has partnerships with over 2,000 pharmaceutical organizations and more than 100 collaborative research projects worldwide.
Funding for Future Development
The new funding will support further development of ai technology platforms and clinical translation of drug candidates.
The bottom line
Sanyou Bio received $15 million (RMB 100 million) Series C funding from Zero2IPO Industry Investment to advance its AI drug discovery platform.
